v3.26.1
Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)
 6 Months Ended
Jun. 30, 2026
Dec. 31, 2025
Schedule of Intangible Assets [Line Items]    
Cost, Balance beginning $ 2,933,932  
Cost, Balance ending 6,380,091  
Accumulated depreciation, Balance beginning 41,535  
Accumulated depreciation, Balance ending 386,276  
Net book value 5,993,815 $ 2,892,397
Cost, Additions 15,000  
Cost, Business combinations 3,431,159  
Accumulated depreciation, Amortization 344,741  
License # 2 (IPR&D asset) [Member]    
Schedule of Intangible Assets [Line Items]    
Cost, Balance beginning [1] 2,072,632  
Cost, Balance ending [1] 2,087,632  
Accumulated depreciation, Balance beginning [1]  
Accumulated depreciation, Balance ending [1]  
Net book value [1] 2,087,632 2,072,632
Cost, Additions [1] 15,000  
Cost, Business combinations [1]  
Accumulated depreciation, Amortization [1]  
Customer relationship [Member]    
Schedule of Intangible Assets [Line Items]    
Cost, Balance beginning 682,300  
Cost, Balance ending 2,475,264  
Accumulated depreciation, Balance beginning 16,946  
Accumulated depreciation, Balance ending 72,684  
Net book value 1,966,784 665,354
Cost, Additions  
Cost, Business combinations 1,792,964  
Accumulated depreciation, Amortization 55,738  
Brand [Member]    
Schedule of Intangible Assets [Line Items]    
Cost, Balance beginning 150,000  
Cost, Balance ending 281,000  
Accumulated depreciation, Balance beginning 14,568  
Accumulated depreciation, Balance ending 34,880  
Net book value 246,120 135,432
Cost, Additions  
Cost, Business combinations 131,000  
Accumulated depreciation, Amortization 20,312  
Backlog [Member]    
Schedule of Intangible Assets [Line Items]    
Cost, Balance beginning 29,000  
Cost, Balance ending 403,054  
Accumulated depreciation, Balance beginning 10,021  
Accumulated depreciation, Balance ending 183,399  
Net book value 120,331 18,979
Cost, Additions  
Cost, Business combinations 374,054  
Accumulated depreciation, Amortization 173,378  
Intellectual properties &certifications [Member]    
Schedule of Intangible Assets [Line Items]    
Cost, Balance beginning  
Cost, Balance ending 1,133,141  
Accumulated depreciation, Balance beginning  
Accumulated depreciation, Balance ending 95,313  
Net book value 1,572,948
Cost, Additions  
Cost, Business combinations 1,133,141  
Accumulated depreciation, Amortization $ 95,313  
[1] On March 24, 2026, the Company entered into a third amendment to an existing license agreement related to License #2. The third amendment to the license agreement revised certain development milestone timelines and milestone payment provisions associated with the licensed products in the human health field. Key changes included clarification that, with respect to the licensed product BLS-M22, the Company may initiate a Phase 2 clinical trial without first initiating a Phase 1 clinical trial, subject to providing supporting scientific, preclinical, or regulatory documentation reasonably acceptable to the licensor. The third amendment further clarified that, if Phase 1 clinical trials are bypassed for BLS-M22, the milestone payment associated with initiation of a Phase 1 clinical trial would become payable concurrently with the milestone payment due upon initiation of a Phase 2 clinical trial. In connection with the third amendment, the Company agreed to pay a one-time, non-creditable and non-refundable amendment fee of $15,000.